Zenas BioPharma Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022
Period Ending	Sep '25 Sep 30, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022
Cash & Equivalents	115.57	319.74	56.86	67.21
Short-Term Investments	175.32	31.02	-	-
Cash & Short-Term Investments	290.88	350.77	56.86	67.21
Cash Growth	-24.80%	516.93%	-15.40%	-
Prepaid Expenses	4.46	3.07	1.65	1.24
Restricted Cash	-	0.09	-	-
Other Current Assets	-	2	1.3	-
Total Current Assets	296.64	355.92	59.8	68.44
Property, Plant & Equipment	0.86	1.19	1.01	1.8
Long-Term Deferred Charges	0.84	-	1.39	-
Other Long-Term Assets	12.97	12.86	5.97	4.33
Total Assets	322.02	369.97	68.18	74.58
Accounts Payable	6.44	17.14	5.4	5.82
Accrued Expenses	45.36	39.16	17.01	19.44
Current Portion of Leases	0.62	0.79	0.56	0.72
Current Income Taxes Payable	-	0.21	0.3	-
Total Current Liabilities	52.42	57.29	23.26	25.97
Long-Term Debt	-	-	20.3	-
Long-Term Leases	0.18	0.22	0.26	0.81
Total Liabilities	125.59	57.51	43.82	26.78
Common Stock	0	0	-	0
Additional Paid-In Capital	721.18	699.65	4.65	1.03
Retained Earnings	-524.69	-387.39	-230.4	-193.28
Comprehensive Income & Other	-0.07	0.19	0.04	-0.04
Total Common Equity	196.43	312.46	-225.72	-192.29
Shareholders' Equity	196.43	312.46	24.37	47.8
Total Liabilities & Equity	322.02	369.97	68.18	74.58
Total Debt	0.8	1	21.11	1.53
Net Cash (Debt)	290.09	349.76	35.74	65.68
Net Cash Growth	-24.93%	878.52%	-45.58%	-
Net Cash Per Share	6.92	26.50	23.34	44.02
Filing Date Shares Outstanding	53.68	41.8	1.58	1.55
Total Common Shares Outstanding	42.21	41.79	1.58	1.55
Working Capital	244.22	298.63	36.55	42.48
Book Value Per Share	4.65	7.48	-143.15	-124.11
Tangible Book Value	196.43	312.46	-225.72	-192.29
Tangible Book Value Per Share	4.65	7.48	-143.15	-124.11

Updated Nov 12, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.

SEC Filings: 10-K · 10-Q